Abbott's UK snafu spotlights social media's role in public health

The latest stories trending on MedCity News.

Editor's Pick

Top Story Recent Abbott Snafu Shines Spotlight on Social Media's Role in Public Health Crisis Response Social media should play a bigger part in public health crisis planning, according to a recent analysis. The analysis explored the crucial role that Twitter and other social media platforms played when the app for Abbott's FreeStyle Libre system crashed earlier this month in the U.K. Sponsored Content What is the ROI for Conversational AI in Patient Access? Presented by Parlance Health systems need to turn their attention to technology that can improve staff retention by reducing employee burnout, according to HCA Divisional CIO Andy Draper. Here's a look at what Parlance is doing to realize ROI with conversational AI. Learn More>> Attendees were Top Notch! A direct quote from an INVEST Digital Health attendee last year. Act now to reserve your lowest price ticket and get in on the action to connect with the best in healthcare. This year's event is October 26th at Pegasus Park in Dallas, TX. Save $200 - Purchase Your Ticket Now

Featured News

A Personalized Approach to Medication Nonadherence At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes. The New Opportunity to Help Rare Disease Patients In 2020, 46.9% of all novel drugs approved by the FDA were for rare diseases, as compared to 23.5% in 2012. Investment is expected to continue trending upward, with estimates suggesting that global spending on rare disease therapies will reach $260 billion by the end of 2025. MedCity Pivot Podcast: Season 2 Launches With A Conversation On the Potential Toxicity of Immunotherapy Transformations in the Life Sciences is the focus of the second season of the MedCity Pivot Podcast. My personal journey as a caregiver of a cancer patient made me choose Dr. Sumanta Pal, co-director of the City of Hope's Liver Cancer program as a guest after he co-authored an interesting study on immunotherapy that was published in the Lancet. Roche Expands Into RNAi Through Alnylam Alliance on Hypertension Drug Alnylam pioneered RNA interference drugs for rare disease. The biotech aims to bring RNAI to prevalent disorders and its alliance with Roche on the drug zilebesiran for hypertension better positions the company to achieve this goal. Closing the Oral Drug Gap Patients are driving the push away from needles, and there are a number of novel approaches attempting to solve the difficult task of transforming biologics into orally administered treatments.

Resources

Sponsored Content 10 Critical KPIs Every Successful Healthcare Organization is Implementing Learn the top 10 most important contract management KPIs and how to maximize their impact Download Now

MedCity News • PO Box 901 • New York, NY unsubscribe